Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database (Q41294004)

29 September 2017

title

Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database (English)

1 reference

29 September 2017

0 references

2

Yazdan Yazdanpanah

1 reference

29 September 2017

1

François Raffi

1 reference

29 September 2017

Francis Fagnani

3

1 reference

29 September 2017

Caroline Laurendeau

series ordinal

4

1 reference

29 September 2017

Antoine Lafuma

series ordinal

5

1 reference

29 September 2017

Julie Gourmelen

series ordinal

6

1 reference

29 September 2017

language of work or name

English

0 references

publication date

22 April 2015

1 reference

Journal of Antimicrobial Chemotherapy

29 September 2017

published in

1 reference

29 September 2017

volume

70

1 reference

29 September 2017

issue

7

1 reference

29 September 2017

page(s)

2121-2128

1 reference

Medication compliance and persistence: terminology and definitions

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIV viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Forgiveness of non-adherence to HIV-1 antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Better adherence with once-daily antiretroviral regimens: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

Factors associated with persistence of cholinesterase inhibitor treatments in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV083

21 January 2018

Identifiers

DOI

10.1093/JAC/DKV083

1 reference

29 September 2017

1 reference